Outpatient Shifts And CMS Changes Will Expand Surgical Potential

Key Takeaways

• Strategic investments in advanced procedures, facility enhancements, and physician recruitment enable above-market growth and position the company to benefit from industry migration trends.
  
• Regulatory tailwinds and disciplined M&A execution are expanding the addressable market, supporting ongoing margin expansion and stronger long-term earnings potential.
  
• Rising debt costs, slower acquisitions, portfolio adjustments, non-controlling ownership of new sites, and regulatory pressures threaten growth, margin expansion, and financial stability.

Catalysts

Owns and operates a network of surgical facilities and ancillary services in the United States.

• The accelerated migration of high-acuity surgical procedures (particularly orthopedics and joint replacements) from hospitals to outpatient settings is strengthening, with Surgery Partners demonstrating outperformance through investments in robotics and facility capabilities, positioning the company to capitalize on expanding case volumes and higher-revenue procedures-directly supporting long-term revenue and EBITDA growth.
  
• Recent and proposed regulatory changes (such as CMS expanding the ASC covered procedure list, phasing out the inpatient-only list, and supporting site-of-care neutrality) are expected to further expand the company's addressable market, enabling more complex and higher-reimbursement procedures to move into their centers, which should positively affect revenue and earnings growth.
  
• Ongoing physician recruitment-particularly targeting orthopedic and higher-acuity specialties-combined with a solid track record of new de novo facility openings, is enabling above-market organic growth in surgical volumes and revenue per case, both of which are likely to drive durable same-facility revenue and earnings expansion.
  
• Disciplined execution on M&A and portfolio optimization, including accretive acquisitions and potential asset sales or health system partnerships, should enhance margin expansion, accelerate deleveraging, and improve free cash flow conversion, supporting improvements in net margins and long-term earnings power.
  
• Investments in operational efficiency and revenue cycle management (e.g., DSO reduction, procurement initiatives) are supporting incremental margin improvement and cash flow conversion, setting the stage for continued net margin expansion as scale and integration benefits compound over the medium term.

Surgery Partners Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Surgery Partners's revenue will grow by 5.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from -2.4% today to 1.2% in 3 years time.
• Analysts expect earnings to reach $45.5 million (and earnings per share of $0.36) by about April 2029, up from -$77.9 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 70.3x on those 2029 earnings, up from -20.0x today. This future PE is greater than the current PE for the US Healthcare industry at 22.0x.
• Analysts expect the number of shares outstanding to grow by 0.74% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.08%, as per the Simply Wall St company report.

Risks

• Rising interest expenses due to the expiration of fixed-rate swaps and exposure to floating rates has led to notable increases in cash outflows for debt service, putting downward pressure on net earnings and cash flow conversion.
  
• The pace of acquisitions is slower than expected, with only a third of the targeted $200 million in capital deployed by mid-year, reducing the incremental EBITDA growth and risking underperformance on stated revenue and earnings guidance should acquisition timing continue to lag.
  
• Portfolio optimization initiatives, including potential divestitures, minority partnerships, or sales of facilities, while aimed at deleveraging, introduce execution risk that could disrupt revenue streams, compress margins, or slow organic growth if not managed carefully.
  
• A substantial portion of new facility development (de novos) is not majority-owned and comes through as management fees or equity earnings rather than consolidated facility revenue, potentially muting direct revenue contribution and limiting margin upside from these growth investments.
  
• Ongoing regulatory changes and payer pressures-such as evolving pre-authorization processes, medical necessity requirements, and shifting reimbursement models-may create compliance burdens, compress pricing power, and introduce volatility in revenue cycles, challenging sustained margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $18.8 for Surgery Partners based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $14.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.9 billion, earnings will come to $45.5 million, and it would be trading on a PE ratio of 70.3x, assuming you use a discount rate of 9.1%.
• Given the current share price of $12.18, the analyst price target of $18.8 is 35.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.